Home / Health / Indian Biotech Startup ImmunoAct Achieves Profitability in First Year
Indian Biotech Startup ImmunoAct Achieves Profitability in First Year
27 Jul
Summary
- ImmunoAct generated ₹62 crore in revenue and ₹12 crore in profit before tax in FY25.
- ImmunoAct's NexCAR19 therapy has been administered to over 350 patients across India.
- NexCAR19 is priced ~90% cheaper than its US and European counterparts.
In a rare feat for India's emerging startup landscape, cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations. The company, in which Hyderabad-based drugmaker Laurus Labs holds a 34% stake, saw revenues of ₹62 crore and a profit before tax of ₹12 crore in FY25.
Founded in 2013 and spun off from IIT Bombay in 2018, ImmunoAct has developed NexCAR19, the first indigenously approved breakthrough cancer CAR-T therapy in India. Launched in April 2024, NexCAR19 is priced around 90% cheaper than its US and European counterparts, making it far more affordable for India and low-and-middle income countries. So far, the therapy has been infused in over 350 patients across 70 hospitals in the country.
ImmunoAct has recently appointed former Roche India managing director V Simpson Immanuel as its strategic advisor, as the company looks to expand its global footprint. The global market for CAR-T therapies is expected to touch $134 billion by 2034, up from around $10 billion currently, presenting significant growth opportunities for innovative players like ImmunoAct.
